Opportunities for improving medication use and monitoring in gout

Annals of the Rheumatic Diseases

Volumn 68, Issue 8, 2009, Pages 1265-1270

  Singh, J A ^a,b   Hodges, J S ^a,c   Asch, S M ^d  

^a VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; COLCHICINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROBENECID; URIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; FEMALE; GOUT; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HUMAN; KIDNEY FAILURE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK; SOCIOECONOMICS; TREATMENT DURATION; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL; VETERAN;

AGED; ALLOPURINOL; BIOLOGICAL MARKERS; COLCHICINE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; GOUT; GOUT SUPPRESSANTS; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROBENECID; QUALITY OF HEALTH CARE; RENAL INSUFFICIENCY; TREATMENT OUTCOME; URIC ACID;

EID: 67651233985     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.092619     Document Type: Article

References (40)

1. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-5.
2. Mikuls TR, Curtis JR, Allison JJ, Hicks RW, Saag KG. Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internetaccessible error reporting system. J Rheumatol 2006;33:562-6.
3. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 2005;44:1038-42.
4. Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang Y. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006;33:104-9.
5. McClintock AD, Egan AJ, Woods DJ, Pillans PI. A survey of allopurinol dosage prescribing. N Z Med J 1995;108:346-7.
6. Smith P, Karlson N, Nair BR. Quality use of allopurinol in the elderly. J Qual Clin Pract 2000;20:42-3.
7. Osterhaus JT, Patel P, Williams AP, Bakst A, Joseph-Ridge N. Patient reported outcomes assoicated with gout: baseline results from two clinical trials. Arthritis Rheum 2005;52(9 Suppl):S401-2.
8. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
9. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57:545-9.
10. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006;12:61-5.
11. Day RO, Miners JO, Birkett DJ, Whitehead A, Naidoo D, Hayes J, et al. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol 1988;26:423-8.
12. Yang W, Sarawate C, Griffith C, Brewer K, Bakst A, Patel P. Ability to attain target serum uric acid level in gout patients on allopurinol. Arthritis Rheum 2005;52(9 Suppl):S410-11.
13. Mikuls TR, MacLean CH, Olivieri J, Patino F, Allison JJ, Farrar JT, et al. Quality of care indicators for gout management. Arthritis Rheum 2004;50:937-43.
14. Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 1989;16:1246-8.
15. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429-32.
16. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twentyeight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, doseresponse clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916- 23.
17. Terkeltaub RA. Clinical practice. Gout. N Engl J Med 2003;349:1647-55.
18. Yu T. The efficacy of colchicine prophylaxis in articular gout: a reappraisal after 20 years. Semin Arthritis Rheum 1982;12:256-64.
19. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
20. Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum 2007;57:822-9.
21. Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis 2006;65:1368-72.
22. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925- 34.
23. Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 2008;67:609-13.
24. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health related quality of life and higher health care utilization in US veterans. Ann Rheum Dis 2008;67:1310-6.
25. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
26. Bennett W, Aronoff G, Gopler T. Drug prescribing in renal failure. American College of Physicians, 1987.
27. Wallace SL, Singer JZ. Review: systemic toxicity associated with the intravenous administration of colchicine-guidelines for use. J Rheumatol 1988;15:495-9.
28. Levine AM, Richardson JL, Marks G, Chan K, Graham J, Selser JN, et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987;5:1469-76.
29. Asch SM, McGlynn EA, Hogan MM, Hayward RA, Shekelle P, Rubenstein L, et al. Comparison of quality of care for patients in the Veterans Health Administration and patients in a national sample. Ann Intern Med 2004;141:938-45.
30. Jha AK, Perlin JB, Kizer KW, Dudley RA. Effect of the transformation of the Veterans Affairs Health Care System on the quality of care. N Engl J Med 2003;348:2218-27.
31. MacLean CH, Louie R, Leake B, McCaffrey DF, Paulus HE, Brook RH, et al. Quality of care for patients with rheumatoid arthritis. JAMA 2000;284:984-92.
32. Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, et al. Longterm adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006;113:203-12.
33. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7.
34. Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med 1961;55:179-92.
35. Emmerson BT. The management of gout. N Engl J Med 1996;334:445-51.
36. Kerr EA, Gerzoff RB, Krein SL, Selby JV, Piette JD, Curb JD, et al. Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD study. Ann Intern Med 2004;141:272-81.
37. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42.
38. Eaton CB, Stamp MJ. Practice patterns related to the Adult Treatment Panel III guidelines in primary care. Am J Cardiol 2002;90:687.
39. Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002;105:152-6.
40. Hoekstra JW, Pollack CV Jr, Roe MT, Peterson ED, Brindis R, Harrington RA, et al. Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. Acad Emerg Med 2002;9:1146-55.